Breonics: Overview Continued
Inc. is an emerging biomedical research and discovery company that
is developing innovative products for the clinical organ transplantation,
tissue replacement and gene therapeutic markets. Incorporated in
1996, the company has built upon strong collaborative and strategic
relationships. Working closely with world renowned clinical transplantation
organizations, research centers and major pharmaceutical companies
provides the resources to overcome development obstacles and rapidly
advance the company's technologies to market.
Cheap research paper writing essays247 on request
was first to focus its efforts on developing technology that overcomes
the barriers to expanding the organ donor pool, thereby offering
a solution to the chronic shortage of organs. Based upon over fifteen
years of research by its founding personnel, the company has 12
issued patents and another 15 pending that cover its proprietary
equipment, methods and processes for resuscitating, evaluating,
repairing and pre-treating organs intended for clinical transplantation.
company is a privately held corporation funded by venture capital,
grants and contracts from the National Institutes of Health, (NIH)
and National Technology Test Bed (NMTB) and research and development
support from strategic partnering. Research revenues for fiscal
years 2008 and 2009 were approximately $1.75 million. Revenues for
2002 are projected to reach $3.3 million. Initial investors include
Techno Ventures Management GmbH, Munich (TVM), Alpinvest and Krediet
Bank Luxembourg (KBL).
facilities include its research and manufacturing park located in
Orange County, New York that provides FDA compliant GMP (Good Manufacturing
Procedure) and GLP (Good Laboratory Procedure) facilities for advanced
product development and manufacture. Cell culture and perfusion
laboratories are located in Schenectady, New York, preclinical research
is conducted at East Carolina University Medical Center, Greenville,
Currently Under Development
company's research and development program includes:
Metabolic Support (EMS), a technology that consists of the proprietary
solutions, equipment and process to resuscitate, evaluate, maintain
and repair warm, ischemically damaged organs and tissue.
Specific Immunosuppression that includes ENDOMATIRX, which may
be the first successful therapy to pre-treat organs prior to
transplantation in order to induce tolerance in the recipient
and eliminate the need for systemic immunosuppression.